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Although significant advances have been made over the
past 30 years in understanding the neurobiology of Alz-
heimer’s disease (AD) and other chronic neurodegenera-
tive disorders, a worldwide public health crisis continues
to grow due to the aging of the world’s population and
the lack of effective interventions. In the United States,
more than five million people currently live with Alz-
heimer’s, including one in nine people greater than the
age of 65 years [1]. The number of Americans with AD
is expected to increase dramatically as the baby boom
generation ages.
The cost of this crisis, both personal and societal, is enor-
mous. In 2014, Medicare and Medicaid are projected to pay
$150 billion for the health care and long-term care of people
with Alzheimer’s and other dementias [1]. During the same
period, out-of-pocket expenses are expected to reach
$36 billion. The total health and long-term care costs across
all payers for seniors with Alzheimer’s and other dementias
($46,669 annually) are more than three times greater than for
other seniors. In addition, more than 15 million Americans
provide 17.7 billion hours of unpaid care giving for people
with Alzheimer’s and other dementias, work that is valued
at $220 billion [1]. Of course, Alzheimer’s is ultimately a
fatal disease. In 2014, an estimated 700,000 Americans
will diewith Alzheimer’s [2]. The magnitude of this growing
crisis demands a commensurate response.Many countries, and international organizations, have
developed national plans and analytical reports to address
the problem [3–5]. In the United States, the National
Alzheimer’s Project Act (NAPA) was signed into law in
2011, calling for the development of a comprehensive
plan to fight AD. This plan, the National Plan to
Address Alzheimer’s Disease (henceforth called “the
National Plan”), was developed by the Department of
Health and Human Services (HHS) with input from
experts in aging and dementia and presented in May
2012 at the Alzheimer’s Research Summit 2012: Path to
Treatment and Prevention [6]. The National Plan outlined
a set of initiatives to provide improved tools for clinicians,
assist caregivers, and individuals with dementia, raise
public awareness about the disease, and critically, to
advance research. It also set an aggressive research goal
to “Prevent and Effectively Treat Alzheimer’s Disease
by 2025.” To achieve this goal, the following strategies
were set:
 Identify research priorities and milestones;
 Expand research aimed at preventing and treating AD;
 Accelerate efforts to identify early and presymptom-
atic stages of AD;
 Coordinate research with international public and
private entities;
 Facilitate the translation of findings into medical
practice and public health programs.
Table 1
Current milestones and their associated success criteria and timelines, as published by HHS and last updated in summer 2013 (available at: http://aspe.hhs.gov/
daltcp/napa/milestones/milestones-p.pdf), along with the new milestones and changes to existing milestones recommended by the expert workgroup
Milestone Success criteria/timeline Suggested changes/notes
A: Convene an advisory meeting of experts from
the pharmaceutical industry, government,
academia, the FDA, and the nonprofit sector to
advance rational drug repositioning and
combination therapy based on translational
bioinformatics and network pharmacology
approaches and to explore opportunities for new
public-private partnerships to facilitate drug
rescue/repurposing and combination therapy.
(1) Development of recommendations for rational
repositioning and combination therapy
development, (2) Development, negotiation, and
implementation of appropriate agreements
among the stakeholders involved in
repositioning and combination therapy of drugs
for Alzheimer’s disease (AD). These agreements
should address legal issues, intellectual property
rights, and liability to expedite rigorous clinical
testing of repurposed drugs.
Timeline: 1 yr; 2014
Extend the time frame and scope of the advisory
committee, and expand representation of
industry scientists.
B: Initiate research programs for translational
bioinformatics and network pharmacology to
support rational drug repositioning and
combination therapy from discovery through
clinical development.
Identification of at least 6 existing drugs suitable
for repurposing and/or combination therapy for
AD prevention or treatment. The drugs selected
for repurposing or combination therapy will be
prioritized based on:
(1) Evidence that theymodulate disease relevant
pathways/networks gained from computational
and empirical approaches.
(2) Preclinical proof-of-efficacy in a relevant
model system.
(3) Availability of biomarkers to monitor target
engagement in humans.
(4) Sufficient evidence of safety for the intended
target population.
Timeline: 3–5 yrs; 2015–2019
Expand to include research on the basic science
underlying combination therapy.
C: Initiate early clinical development for at least 6
existing drugs or drug combinations for the
treatment or prevention of AD.
Completion of at least four Phase II trials with
repurposed drugs and/or drug combinations.
Successful trials will provide conclusive
evidence of therapeutic mechanism/target
engagement.
Timeline: 2–4 yrs; 2018–2021
Note: Contingent on successful completion of
Milestones A and B; therefore unable to address
feasibility at this time.
D: Initiate at least three Phase III trials with
repurposed drugs or drug combinations. Of
these at least one trial will be in an
asymptomatic at-risk population and at least one
for individuals with advanced disease. Of the
trials initiated in patients with advanced disease,
at least one trial will target the neuropsychiatric
symptoms of AD.
Comprehensive success/failure analyses of data
from at least three Phase III trials.
Timeline: 3–5 yrs; 2020–2024
Note: Contingent on successful completion of
Milestones A and B; therefore unable to address
feasibility at this time.
E: Initiate Phase II (proof of concept) drug trials for
agents against three to six currently known
therapeutic targets. Of these at least two will be
for targets involved in asymptomatic stages of
disease. These trials will be designed to provide
or confirm proof of mechanism and/or evidence
of target engagement for the therapeutic agent
being tested.
Completion of three to six Phase II drug trials for
agents against currently known targets,
providing conclusive evidence of therapeutic
mechanism/target engagement.
Timeline: 2–4 yrs; 2015–2018
Revise the milestone to reflect a number of Phase II
drug trials that will need to be initiated to
achieve completion of three to six trials that
show evidence of therapeutic mechanism/target
engagement.
Delete the requirement that trials will be for
targets involved in asymptomatic disease (see
note).
F: Initiate Phase III drug trials for agents against
at least three currently known therapeutic
targets. Of these at least one trial will be
asymptomatic, at risk populations. These
trials will incorporate a combination of
biomarkers (fluid and imaging) and
cognitive measures as outcomes and
include collection of DNA and other
biosamples for interrogation of
responsiveness.
Comprehensive success/failure analysis of data
from at least three Phase III trials.
Timeline: 3–5 yrs; 2017–2021
Revise the milestone to reflect a number of Phase
III drug trials that will need to be initiated to
maximize the likelihood of a successful trial.
Add wording to the effect that at least one trial
will be of a symptomatic therapy.
Note: Public-private partnerships, similar to
those created for ongoing predementia trials
(e.g., DIAN-TU, API, A4) will be needed to
achieve this milestone.
(Continued )
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G: Establish a searchable, open access research
database that contains all clinical, biomarker,
and epidemiological data, and related genotypes
and phenotypes from existing genetic studies;
analyze these data to identify regions of the
genome that are targets for AD therapeutics.
At least one novel target, pathway or therapeutic
approach identified through use of the database.
Timeline: 4–5 yrs; 2013–2017
Expand the analysis of data beyond identifying
genomic regions (to include, for example,
epigenetic data), and expand the success criteria
to 12 rather than one novel target identified.
H: Establish a consortium of genetics and
genomics experts to develop and execute a large
scale sequencing project to analyze the genomes
of a large number of well characterized
individuals including multiethnic subjects using
next generation sequencing approaches; identify
a broad range of AD risk and protective gene
variants in subjects with late onset AD (LOAD).
Identification of new risk and protective alleles for
LOAD that lead to the identification of at least
one novel therapeutic approach, drug target or
pathway for prevention.
Timeline: 5–8 yrs; 2013–2020
New: Develop a uniform protocol for collecting,
storing, and providing open access to
biospecimens for use in genetics, proteomics,
and other biomarker studies.
I: Identify, characterize, and complete early
validation for at least six novel therapeutic
targets for AD (a minimum of three targets for
presymptomatic and early stage disease and a
minimum of three for advanced disease).
Validation based on availability of the following for
each novel target: a systems-level understanding
of the gene, protein and metabolic networks
within which they operate, one or more cell
based/animal models that are freely available to
the research community, a quantitative
assessment of the integrative response to the
modulation of the target in one or more model
organisms, and identification of
pharmacodynamic biomarker(s) for target
engagement.
Timeline: 5–7 yrs; 2014–2020
Expand the number of novel therapeutic targets to
be identified, characterized, and validated to 60
NMEs covering six new classes of targets (e.g.,
inflammation, tau, etc.)
Note: Past history shows that only a fraction of
NMEsmake it from preclinical stage to Phase III
trials; therefore, a much larger number of NMEs
need to be identified. Moreover, novel targets
need to be identified across many pathways and
mechanisms.
J: Initiate drug discovery efforts to develop novel
therapeutic agents against at least six novel
therapeutic targets (a minimum of three targets
for presymptomatic and early stage disease and
a minimum of three for advanced disease).
Complete preclinical development, through IND
filing, of therapeutics agents against at least 3
novel targets.
Timeline: 5–7 yrs; 2017–2023
Expand the number of therapeutic agents
developed to 30.
K: Initiate Phase II (proof of concept) drug trials
for agents against three to six novel therapeutic
targets. These trials will provide proof of
mechanism and/or evidence of target
engagement of the target being tested.
Completion of three to six Phase II drug trials for
agents against novel targets, providing
conclusive evidence of therapeutic mechanism/
target engagement.
Timeline: 2–4 yrs; 2020–2023
Expand the number of agents advanced to Phase II
trials to at least 12.
L: Initiate Phase III drug trials for agents against at
least three novel therapeutic targets. These trials
will incorporate a combination of biomarkers
(fluid and imaging) and cognitive measures as
outcomes and include the collection of DNA and
other biosamples for the interrogation of
responsiveness.
Comprehensive success/failure analysis of data
from at least 3 Phase III trials.
Timeline: 3–5 yrs; 2022–2026
Ensure that at least one of the agents tested in a
Phase III study is for a symptomatic indication.
New: Enlist an unbiased, independent, nonprofit
entity to conduct an annual review of clinical
trial efficiencies.
New: Convene a working group to consider novel
trial designs including adaptive trials.
(Continued )
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M: Convene an advisory meeting to delineate an
interdisciplinary research agenda focused on:
(1) advancing nonpharmacological
interventions for the cognitive and behavioral
symptoms of AD by nonpharmacological
treatments, (2) informing the design of
therapeutic approaches combining
pharmacological and nonpharmacological
treatments and (3) identification of best
practices for implementation of non-
pharmacological interventions.
Recommendations developed for advancing non-
pharmacological interventions for AD treatment
and prevention to enable successful
implementation of effective
nonpharmacological interventions.
Timeline: 1 yr; 2014
Revise wording to include not only cognitive and
behavioral symptoms, but also functional and
psychological symptoms of AD; and to develop
best practices across the continuum of the
disease, in different settings, and in the presence
of comorbid conditions.
N: Convene an advisory meeting to inform the
design of therapeutic approaches combining
pharmacological and nonpharmacological
treatments.
Recommendations developed for the design of
clinical trials combining pharmacological and
nonpharmacological interventions.
Timeline: 1 yr; 2015
Revise wording to include a range of treatment
targets (medical, psychosocial, behavioral,
environmental, and caregiver training) for the
behavioral, psychological, cognitive, and
functional symptoms of AD.
O: Initiate interdisciplinary research programs that
integrate epidemiological and mechanistic
research including cutting edge systems biology
approaches to gain an in depth understanding of
the mechanisms by which various
nonpharmacological interventions impact brain
health and the course of AD.
Identification of at least three new therapeutic
targets for neuroprotection based on knowledge
of mechanisms mediating the impact of
nonpharmacological interventions of brain
health in aging and AD. Preclinical proof-of-
concept for at least 3 types of
nonpharmacological interventions that can
inform clinical trial design.
Timeline: 5 yrs; 2016–2020
Include clinical research and biomarker studies in
the integrated interdisciplinary research
programs; and in the goals of the research, add
developing a theoretical rationale for
mechanisms by which interventions impact
brain health and the course of disease.
P: Initiate clinical trials for at least three
nonpharmacological interventions aimed at AD
prevention. Of these at least one trial will be a
pivotal, Phase III trial.
Completion of at least two Phase II trials for
nonpharmacological interventions aimed at AD
prevention. Successful trials will provide
conclusive evidence of therapeutic mechanism.
Comprehensive success/failure analysis of data
from at least one Phase III trial.
Timeline: 4–5 yrs; 2017–2021
Include biomarker studies in clinical trials.
Q: Initiate clinical trials for at least three
interventions combining pharmacological and
nonpharmacological interventions for AD
treatment or prevention. Of these at least one
trial will be a pivotal, Phase III trial.
At least two Phase II trials completed for
interventions combining pharmacological and
non-pharmacological interventions for AD
treatment or prevention with conclusive
evidence of therapeutic mechanism.
Comprehensive success/failure analysis of data
from at least one Phase III trial.
Timeline: 4–5 yrs; 2019–2023/
Include biomarker studies in clinical trials.
R: Review results of past and existing grants to
develop technologies that promote prevention
and treatment trials. Assess areas where
technologies have been adopted, where there are
promising results that should be followed up,
and where there are remaining needs.
At least two new technologies are developed, prove
useful in formal or informal care, and are widely
adopted.
Timeline: For first: 1 yr; 2015
In description of technologies to be reviewed,
include those with therapeutic potential (e.g.,
technologies used for cognitive training,
promoting or supporting physical activity, or
those used as part of a reminiscence, art, or
music therapy program.
New: Initiate research programs (R01), Small
Business Innovative Research (SBIR), or Small
Business Technology Transfer (STTR) focused
on developing and testing new technologies or
modifying and testing existing technologies to
support the development of nonpharmacologic
therapies (e.g., cognitive training, exercise
technologies, etc.).
At least two new technologies are developed, prove
useful in the development of nonpharmacologic
therapies, and are widely adopted.
(Continued )
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S: Initiate synthesis and testing of novel PET
ligands and develop and test novel CSF/blood
biomarkers for assessment of disease related
pathological burdens such as tau, inflammation,
synaptic dysfunction.
Development and testing of three to five novel PET
ligands and/or CSF/blood biomarkers for
assessment of AD pathology.
Timeline: 5 yrs; 2014–2018
T: Initiate development of imaging and/or
fluid biomarkers to demonstrate target
engagement for 5 novel therapeutic targets
for AD.
Identification of 3 imaging and/or fluid biomarkers
for which there is proof of engagement of novel
therapeutic targets.
Timeline: 5 yrs; 2014–2018
U: Incorporate imaging and/or fluid
biomarkers into Phase II (proof of concept)
drug trials to provide proof of mechanism
and/or evidence of target engagement as
trials for three to six existing and three
to six novel therapeutic targets are
initiated
Initiation and completion of 5 Phase II (proof of
concept) drug trials using imaging and/or fluid
biomarkers for proof of target engagement.
Timeline: 3–5 yrs; 2017–2021
V: Incorporate imaging and/or fluid biomarkers
into Phase III (pivotal) drug trials to select
subjects and/or provide evidence of target
engagement as trials for three to six existing and
three to six novel therapeutic targets are
initiated.
Initiation of three Phase III (pivotal) drug trials
using imaging and/or fluid biomarkers to select
at risk subjects and/or for proof of target
engagement.
Timeline: 3–5 yrs; 2019–2023
W: Biomarkers usable in community studies.
Initiate studies to develop minimally invasive
biomarkers for detection of cerebral
amyloidosis and other AD pathophysiology.
Development and testing of five biomarkers that
utilize biofluids or other minimally invasive
imaging, electrophysiological recording, or
other methodologies to assess the burden of AD
pathophysiology that could be used in
community based and epidemiological studies
of AD.
Timeline: 5 yrs; 2015–2019
Biomarkers should not only be minimally invasive
but also portable and inexpensive to enable large
studies in diverse populations.
X: Linking peripheral and central biomarkers
Initiate studies to link peripheral blood-based
biomarkers and central imaging and CSF
biomarkers.
Identification of three peripheral blood-based
biomarkers that have a high correlation with
central imaging and/or CSF biomarkers.
Timeline: 5 yrs; 2016–2020
Expand the success criteria to call for identifying
five peripheral blood-based biomarkers that
correlate with central (imaging or CSF)
biomarkers.
Note: Three may be insufficient to detect both
cerebral amyloidosis and neurodegeneration,
inflammation, and other pathologies.
Y: Launch research programs to develop and
validate sensitive neuropsychological
assessment measures to detect and track the
earliest clinical manifestations of AD.
Development of at least one sensitive
neuropsychological assessment measure that
has been validated for the detection or tracking
of the earliest clinical manifestations of AD.
Timeline: 5 yrs; 2014–2018
Split or expand milestone and associated success
criteria to differentiate neuropsychological
assessment measures used for screening/
enrichment vs. those used to assess treatment
response.
Z: Biomarker standardization develop and test
methods for the standardization of
immunoassays and mass-spectrometry/single
reaction monitoring assay or other
methodologies for CSF amyloid beta (Ab) and
tau and other biomarkers as they become
clinically applicable. Develop and test methods
for standardization of collection and analysis of
MRI and PET neuroimaging data.
CLIA laboratory qualification in US and the
equivalent certification in the EU for at least one
CSF biomarker of disease pathology. For
neuroimaging data, qualification of at least one
biomarker for use in clinical trials by the FDA
and/or the EMA.
Timeline: 5 yrs; 2014–2018
New: Validate minimally invasive biomarkers in
community studies.
(Continued )
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Milestone Success criteria/timeline Suggested changes/notes
New: Expand existing incentives for
commercialization (e.g., expanding the funding
for SBIR/STTR grants by at least 100%),
providing tax credits, and exploring new ways to
make commercial/capital investment more
accessible for companies wishing to compete in
the highly regulated marketplace of medical
devices.
New: Establish a public-private partnership to
develop mechanisms that will enable data
sharing and protection or sharing of intellectual
property among drug and biomarker developers.
New: Convene a conference/expo that brings
together researchers and companies developing
technologies to capture and analyze everyday
performance measures with clinical
investigators. The goal of this conference would
be to 1) enable cross-silo discussions that would
promote collaborations across the various
stakeholders groups, 2) explore challenges that
need to be addressed to make best use of these
new technologies, including privacy concerns,
establishing validity, and aggregating and
analyzing data.
New: Establish criteria for publishing cognitive
data to enable aggregation of data in real time to
enable comparison across studies.
AA: Establish an expert panel of epidemiologists
and clinical trialists to make recommendations
for best practices in the use of existing
epidemiology of dementia databases to
individualize treatments in clinical trials for AD
in heterogeneous populations.
Clinical trialists and epidemiologists implement
best practices and work together in the design of
clinical trials for AD.
Timeline: 1 yr; 2014
Extend the time frame of the expert panel and
modify the focus to “for prevention of cognitive
impairment and dementia” rather than “in
clinical trials for AD.”
Expand the scope of the panel’s work to include
determination of the best targets for prevention
and the time in the lifespan when prevention
trials make the most sense.
AB: Initiate expansion of epidemiology of
dementia cohorts to include subjects in midlife
and use data generated to inform clinical trial
design.
Three or more active cohorts that cover age range
frommidlife to late-life as a study population for
investigating and reporting findings on changing
risk profiles from younger to older ages.
Timeline: 5–7 yrs; 2014–2020
Expand the cohorts to include subjects from
heterogeneous populations across the life-
course, beginning earlier than mid-life, and
expand the research on these cohorts to include
investigations of early exposures, genetics,
cumulative risk exposures, epigenetics, and
modifiable risk factors.
Note: Timeline for these studies must extend
beyond 5 yrs; therefore it will be essential to
identify sustaining funding mechanisms.
New: Establish a working group to harmonize data
collection across epidemiologic studies so that
data can be combined and compared.
New: Fund a multidomain prevention trial in the
United States focused onmodifiable risk factors.
(Continued )
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Milestone Success criteria/timeline Suggested changes/notes
AC:Develop a commonAD research ontology, as a
unified classification system for comparative
analysis of research portfolios, and strategic
planning, and create a publicly available
database that will house the AD research
portfolios from AD funding agencies in the US
and abroad.
Recruitment of all federal and nonfederal funding
agencies in the US and AD funding agencies
from countries that have an AD National Plan to
participate in this database.
Timeline: 2–3 yrs; 2013–2014
Extend the timeline because both CADRO and
IADRP will need continuous revisions. Include
the development of tools that enable funders to
track and analyze their research investments.
AD: Convene an advisory meeting focused on
facilitating public-private partnerships aimed at
accelerating the development and test of
effective therapies for AD treatment and
prevention.
Established working groups on: (1) rapid data
sharing and analysis, (2) enabling bidirectional
translation in AD drug development, (3)
eliminating intellectual property (IP) barriers for
target validation through clinical proof of
concept.
Timeline 1 yr; 2013
Continue support for this process to promote
additional dialog and effort with the goal of
developing an action plan with concrete steps.
AE: Convene meetings of the working groups for
(1) rapid data sharing and Analysis, (2) enabling
bidirectional translation in AD drug
development, (3) eliminating IP barriers for
target validation through clinical proof of
concept. Each working group will formulate
concrete steps needed to accelerate the time
frame of AD drug development.
Recommendations developed on (1) the creation of
an open access, web based resource that
integrates complete, diverse multidimensional
biological and chemical data that will be useful
in advancing information on drug targets,
including mechanistic information that will aid
in the development of measures of target
engagement (PD readouts); (2) creation of
computational tools for development of
biological network models of AD and normal
aging; (3) creation of tools that will foster
development of bio networkmodels that provide
a predictive framework for using drugs in
combination or singly (4) removing legal and IP
barriers surrounding data sharing. One or more
partnerships established to accelerate key steps
in AD drug development.
Timeline: 1 yr; 2014
AF: Create a network of translational centers that
bring together expertise and technology needed
for integration of multimodal data analysis,
mathematical modeling and empirical testing
and apply a systems biology/systems
pharmacology approach to the most challenging
aspects in preclinical therapy development such
as: (1) therapeutic target selection and initial
target validation, (2) predictive toxicology, (3)
rigorous preclinical efficacy testing and
development of translatable, preclinical
biomarkers. The centers will provide training
programs for the new generation of translational
scientists.
Creation of at least three Translational Centers that
will apply the principles of quantitative and
systems pharmacology to AD drug
development.
Timeline: 3–5 yrs; 2014–2018
Revise the success criteria to include expansion of
the ADCs program with funding for three
demonstration projects to develop
Comprehensive ADCs (CADCs).
AG: Establish an National Institutes of Health
(NIH) working group to develop an expedited
review track for translational AD research
applications (from target identification/
validation drug discovery through Phase III
clinical trials).
New NIH policy in place for fast tracking of AD
translational research application.
Timeline: 1 yr; 2015
New: Convene a workgroup to interact with the
NIH to ensure that the NIH policy on expedited
review includes and achieves specific timeline
targets.
(Continued )
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Table 1
Current milestones and their associated success criteria and timelines, as published by HHS and last updated in summer 2013 (available at: http://aspe.hhs.gov/
daltcp/napa/milestones/milestones-p.pdf), along with the new milestones and changes to existing milestones recommended by the expert workgroup
(Continued )
Milestone Success criteria/timeline Suggested changes/notes
New: Mandate additional NIH funding to support
five translational Alzheimer’s projects per year.
AH: Create a national IRB. Initiation of at least one multicenter clinical trial
that utilizes a national IRB.
Timeline: 2 yrs; 2014–2015
New: Convene a national symposium on the
centralized IRB process, with representation
from universities and other research institutions,
government, industry, and philanthropic
organizations, to 1) increase awareness and
address potential concerns of research
institutions, and 2) coordinate appropriate seed
funding to launch the national IRB.
AI: Establish a working group to identify standard
outcome measures necessary for data
comparisons across a variety of clinical studies.
Identification of at least two standard outcome
measures for data comparison in clinical
research.
Timeline: 1 yr; 2014
Merge Milestones AI and AJ as follows:
Standardize clinical trial outcome measures to
facilitate comparisons across trials and thereby
increase the efficiency and success of trials by (1)
establishing a forum for open sharing of data,
procedures, and analysis of outcome measures; (2)
initiating validation studies across different stages
of disease (preclinical, mild cognitive impairment,
dementia) that incorporate a variety of outcome
measures, with agreement to share data and data
analyses; and (3) developing the infrastructure to
incorporate selected outcome measures into
therapeutic trials.
AJ: Initiate three to four clinical research studies
using common standard outcome measures.
Data comparisons conducted from clinical studies
using common standard outcome measures.
Timeline: 3–5 yrs; 2014–2018
New:Convene a working group that will work with
global partners to develop a strategy for sharing
and harmonizing data across borders.
AK: Increase knowledge among research scientists
of best practices for recruitment and retention of
research participants.
Central resources for both references and tools,
including videos and presentation materials
created and available.
Timeline: 2 yrs; 2014–2015
AL: Establish a working group including clinical
trial recruitment experts to dynamically evaluate
and update the materials and information
provided in the central resource.
Recommendations for successful recruitment
methods.
Timeline: 1 yr; 2014
AM: Increase awareness of large-scale registries
that encompass the spectrum of the disease from
healthy to at-risk asymptomatic to symptomatic
individuals from early midlife to late life willing
to participate in clinical research aimed at AD
prevention and treatment.
A central repository of AD related registries and
cohorts created and publicized.
Timeline: 2 yrs; 2014–2015
Success criteria should include development of
tailored awareness campaigns for different
population groups about the purpose of
registries and the importance of participation.
AN: Increase the rate of enrollment for AD clinical
trials and increase the participation of
underrepresented populations.
Increased rates of enrollment and inclusion of
underrepresented populations for AD clinical
trials as evaluated using the existing NIH system
for NIH funded clinical research.
Timeline: 5 yrs; 2014–2018
Success criteria should include establishment of a
national health promotion campaign, and
regional campaigns to increase awareness and
participation of the African American and
Latino communities.
New: Establish and fund multiple training awards
(e.g., K awards), fellowships, and R01s in the
neuropathology and molecular biology of aging
over the next 5 yrs.
(Continued )
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Table 1
Current milestones and their associated success criteria and timelines, as published by HHS and last updated in summer 2013 (available at: http://aspe.hhs.gov/
daltcp/napa/milestones/milestones-p.pdf), along with the new milestones and changes to existing milestones recommended by the expert workgroup
(Continued )
Milestone Success criteria/timeline Suggested changes/notes
New: Fund a substantial research program on the
basic biology of aging, to include studies of
vulnerabilities in the aging brain, vasculature
changes and endothelial failure, neural
networks, and the biological underpinnings of
“superaging.”
New: Dramatically increase activity and resources
applied to understanding the basic cellular and
molecular biology of Alzheimer’s disease,
including how these processes interact with
aging.
New: Convene a working group/think tank to
reexamine conceptual models of disease beyond
amyloid.
New: Define a path to validate at least one
biomarker capable of predicting clinical
outcome and meet conditions for an accelerated
approval pathway by 2016; and define a path to
achieve regulatory acceptance of this marker as
a surrogate marker.
New: Regulatory “qualification” of three or more
markers of disease progression for application to
stratification of subjects in clinical trials
by 2017.
New: Regulatory “white paper” or other
communication, short of guidelines, giving
sense of regulators to establish appropriate
principles as to degree (especially duration and
sample size) of safety data before allowing years
of treatment of a potentially disease preventing
compound.
New: NIH/NIA/AA and other groups jointly
convene a workshop or summit to lay the
groundwork for creating a precompetitive
consortium of industry partners aimed at de-
risking novel targets through the proof of
concept stage by sharing data and research tools.
Timeline: 1 yr.
New: Create a consortium of industry scientists to
systematically assess, stack rank, and prioritize
existing targets and conduct medicinal
chemistry studies to optimize compounds that
engage these targets.
New: Direct HHS to convene summit of FDA,
industry lawyers, and advocacy groups to devise
incentives that would facilitate data and
resource sharing, and find solutions to issues
related to exclusivity.
Abbreviations: DIAN-TU, Dominantly Inherited Alzheimer Network Trials Unit; API, the Alzheimer’s Prevention Initiative; A4, autosomal dominant
Alzheimer’s Disease trial, the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study; NME, new medical entities.
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interim milestones to provide a roadmap toward achieving
the research goal of the National Plan.
NAPA established an Advisory Council, comprising both
federal and nonfederal members, to help shape the National
Plan and regularly review and monitor implementation of
the Plan. Supplementing the work of the Council, the
Alzheimer’s Association established an expert workgroup
to provide an independent and comprehensive analytical
report on progress in the research arena and craft a scientific
agenda to inform the Council’s recommendations. In
August, 2012, the workgroup published a goal-directed,
10-year scientific agenda intended to aid in the implementa-
tion of the National Plan [7].
Notably, neither NAPA nor the National Plan mandate
the appropriation of funds to achieve the stated goals. To
address the funding required to ensure the success of the
research plan, the Alzheimer’s Accountability Act of
2014 was introduced in Congress on April 1, 2014, and
would require the Director of the National Institutes of
Health (NIH) to submit an annual budget to the President
and to Congress stipulating the funds that are needed to
achieve the research goal of the National Plan.
In June 2014, the Alzheimer’s Association convened an
expert workgroup (the Alzheimer’s Association National
Plan Milestone Workgroup) to re-evaluate the milestones
set forth in the National Plan, determine whether the field
is on track to achieve these milestones, recommend changes
in the parameters of the milestones, identify unaddressed
gaps, and recommend additional milestones to fill these
gaps. The workgroup consisted of world-renowned experts
in AD research and policy. This report from the expert work-
group should inform HHS and Congress in making decisions
about the activities and resources that are needed now to
achieve the National Plan research goal of preventing and
effectively treating AD by 2025, which is a scant decade
away.
The premise of this report is that despite significant chal-
lenges associated with AD research, the scientific commu-
nity remains more optimistic than ever about the potential
success of a focused National Plan, if the appropriate mile-
stones are established and if the appropriate resources are
dedicated to carry out the strategies set forth therein. Many
prominent investigators believe the prospect of delaying
the onset of disabling symptoms within a decade is an attain-
able goal, provided we can surmount several scientific,
administrative, and most importantly, financial impedi-
ments. Although the scientific community and the National
Plan agree that major changes are needed in areas such as
novel conceptual models of the disease, and new strategies
for addressing scientific, administrative, regulatory, and in-
frastructural obstacles, the fact remains that overcoming
these challenges will require a substantial financial invest-
ment. Inadequate funding remains the single most important
impediment to progress in achieving the research goal of the
National Plan.Table 1 summarizes the key milestones proposed by the
Advisory Council, their success criteria, and the projected
time frame for achieving each milestone. It also includes
the revisions recommended by the expert workgroup, both
to existing milestones and suggested new milestones. The
existing milestones have been assigned identifiers (A, B,
C, etc.) for the ease of reference in this document.2. Targets, interventions, and biomarkers
Milestones A through Z address issues related to drug
development for both currently known and new targets,
repurposing and combination therapy, nonpharmacologic
interventions, and biomarkers.2.1. Development of targets and interventions2.1.1. Drug development: Repurposing and combinations
Milestones A through D focus on two aspects of therapy
development: repurposing existing drugs for new indica-
tions, and combining two or more agents to achieve additive
or synergistic effects. Both of these approaches have been
used successfully to treat other disease indications but
have not been applied extensively to neurological disorders.
The potential advantages of repurposing (also called re-
positioning) drugs for the treatment of AD include the avail-
ability of existing preclinical data on safety, tolerability,
pharmacokinetics, and pharmacodynamics of compounds.
For drugs that are on the market, issues related to formula-
tion and manufacturing may also have been solved, and
extensive clinical data may be available [8]. Through a sys-
tematic review of published literature and a Delphi-type
consensus process with industry experts, Corbett et al. [8]
identified and prioritized several classes of drugs that might
be considered in repurposing studies for Alzheimer’s, and
the gaps in knowledge that need to be addressed.
A major roadblock to repurposing is that there may be lit-
tle or no incentive for pharmaceutical companies to devote
resources to drugs for which patent life has expired. The
NIH has stepped into this breach through the Alzheimer’s
Disease Cooperative Study (ADCS) and through the work
of the National Center for Advancing Translational Science
(NCATS), the newest institute of the NIH. NCATS has begun
to inventory, in a systematic manner, data on compounds that
have been approved by international regulatory agencies or
registered for clinical trials [9].
With regard to combination therapy, several recent global
initiatives have suggested including drug combinations as
arms in future adaptive trial designs, and at least one combi-
nation trial—combining a beta-site APP cleaving enzyme
(BACE) inhibitor with an anti-amyloid antibody—has
been reported [10]. In addition, the Food and Drug Admin-
istration (FDA) has signaled its interest in considering com-
bination therapy through the issuance of a guidance on
codevelopment [11,12]. However, combination therapy
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scientific rationale for combining certain therapies, the
need for appropriate biomarkers to assess treatment
effects, new trial designs, and the need for increased
collaboration among industry partners. It should be noted
that substantial basic science resources will need to be
committed in order to understand the complex dynamics
of targeting multiple molecular pathways, and how
biomarkers may respond to combination therapies.
Thus, the steps outlined in Milestone A have not yet been
successfully completed, and the expert workgroup recom-
mends that more effort is needed to address industry con-
cerns about intellectual property. The expert workgroup
further calls for the expansion of Milestone B, noting that
the field may not yet be ready for translational efforts given
the insufficient understanding of the basic science underly-
ing combination therapy. In addition, increased representa-
tion from industry is needed for the successful
implementation of both Milestones A and B. Given that
Milestones C and D are contingent on the work addressed
in A and B, the expert workgroup notes that it is too soon
to address conducting Phase II and III trials of combination
therapies.
Recommended modifications to existing milestones:
 In Milestone A, extend the time frame and scope of the
advisory committee, and expand representation of in-
dustry scientists.
 Expand Milestone B to include research on the basic
science underlying combination therapy.
2.1.2. Drug development: Currently known targets
Milestones E and F concern the development of drugs
against currently known targets. Milestone E calls for initi-
ation of three to six Phase II drug trials against currently
known targets, at least two of which should be in asymp-
tomatic subjects. Although a number of Phase II trials
have already been completed, most of them have targeted
amyloid, and much more needs to be done to test nonamy-
loid therapeutic targets, including tau, inflammation, nico-
tinic agonist receptors, and others. Moreover, given the
high attrition rate in Phase II trials to date [13], to achieve
the success criteria (i.e., completion of three to six Phase II
trials, “providing conclusive evidence of therapeutic mech-
anism/target engagement”) perhaps 12 or more trials will
need to be initiated. The milestone also calls for trials of
agents against three to six therapeutic targets, so these tri-
als will need to involve targets beyond amyloid. Finally,
because of the difficulty of conducting Phase II trials in
asymptomatic subjects, it is more likely that studies to
confirm proof of mechanism and/or evidence of target
engagement would be embedded into Phase III trials that
could be counted as registration trials by the FDA. Such
trials might use an adaptive design whereby a biomarker
of drug effect is included for adjusting dose and/or
declaring futility.Milestone F calls for initiation of Phase III trials against at
least three known targets, with at least one of these trials in
asymptomatic, at risk subjects; and for the inclusion of bio-
markers and cognitivemeasures and the collection of biolog-
ical samples. Currently four asymptomatic Phase III trials
are underway (Dominantly Inherited Alzheimer Network
Trials Unit [DIAN-TU], the Alzheimer’s Prevention Initia-
tive [API] autosomal dominant Alzheimer’s Disease trial,
the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s
Study [A4], and the TOMMORROW study). The TOM-
MORROW study is testing pioglitazone, whereas the three
others target amyloid. All include extensive biomarker and
cognitive testing and the collection of biospecimens. The
expert workgroup noted that these trials have been made
possible only through partnerships bringing together re-
sources from both public and private arenas.
Drugs against several targets beyond amyloid have been
explored as symptomatic therapies, including muscarinic
and other cholinergic agonists and serotonin receptor li-
gands. Although the focus of many ongoing Alzheimer’s tri-
als is on disease modification, symptomatic approaches may
provide substantial benefits to people with AD, including
maintaining function, staying active, and remaining at
home longer as the disease progresses. Moreover, clinical
trials of symptomatic therapies can be completed in less
time and with fewer subjects, thus potentially expediting
the development and approval of new therapies.
Recommended modifications to existing milestones:
 ReviseMilestone E to reflect the large number of Phase
II drug trials that will need to be initiated to achieve
completion of three to six trials against different ther-
apeutic targets that show evidence of therapeutic
mechanism/target engagement.
 In Milestone E, delete the requirement that at least two
trials will be for targets involved in asymptomatic dis-
ease.
 Revise Milestone F to reflect the large number of Phase
III trials that will need to be initiated to achieve three
successful trials.
 Revise Milestone F to indicate that at least one trial
should be of a symptomatic therapy.2.1.3. Drug development: Novel targets
Milestones G through L focus on developing novel targets
into effective treatments. G and H together aim to identify
genetic markers and pathways that may represent therapeu-
tic targets by establishing and analyzing data in an open ac-
cess research database containing multidomain information
(clinical, biomarker, epidemiological, genetic), and devel-
oping a broad, large-scale sequencing project to identify
risk and protective gene variants in late onset AD (LOAD).
Progress has been made in both of these efforts. For
example, the International Genomics of Alzheimer’s Project
used data from four consortia in the United States and
Europe to conduct a meta-analysis of the genotypes of
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Alzheimer’s susceptibility loci [14]. In addition, the Global
Alzheimer’s Association Interactive Network (GAAIN) was
created in 2013 as a federated, cloud-enabled infrastructure
to bring multiple data sets together and provide researchers
with access to both data and analytical and computational
tools [15]. However, there remain challenges to accessing
and using this information. Moreover, the expert workgroup
suggested expanding the databases beyond genetic studies
and the goal beyond the identification of gene variants.
Also needed is a uniform protocol for collecting, storing,
and providing open access to biospecimens for use in ge-
netics, proteomics, and other biomarker studies. In addition,
the success criteria should be expanded from “at least one
novel target. identified” to at least a dozen novel targets
or pathways.
The expert workgroup supported the overall goals of
Milestones I through L, but commented that history shows
that only about 13% of new molecular entities (NMEs)
make it from the preclinical stage to Phase III trials
[16]. This suggests that to achieve the success criteria of
Milestone L (“comprehensive success/failure analysis of
data from at least three Phase III trials”), approximately
23 NMEs would need to be identified, characterized, and
validated in Milestone I, which currently calls for only
six novel therapeutic targets. Moreover, because novel tar-
gets need to be identified across many pathways and
mechanisms—e.g., reducing amyloid, reducing inflamma-
tion—a much larger number of NMEs, 60, should be iden-
tified in Milestone I. Thus, the expert workgroup
recommends that the numbers and projected costs in I, J,
K, and L be adjusted to more accurately reflect the reality
of drug development.
The expert workgroup also noted the need to dramatically
increase the efficiency of Phase II and III trials to change the
risk profile for drug development and spur investment.
Although someof these efficiencies are addressed inothermile-
stones—for example, implementing a National Institutional
Review Board (IRB) (Milestone AH), and convening advisory
meetings andworking groups to address some of the barriers to
drug development (Milestones AD and AE)—more activity
and resources are needed in this area. Additional milestones
are also recommended for developing precompetitive consortia
tode-risk the early stages ofdrugdevelopment (see section5.3).
Recommended modifications to existing milestones:
 In Milestone G, expand the analysis of data beyond
identifying genomic regions (to include, for example,
epigenetic data), and expand the success criteria to
12 rather than one novel target identified.
 In Milestone I, expand the number of novel therapeutic
targets to be identified, characterized, and validated to
60 NMEs covering six new classes of targets (e.g.,
inflammation, tau).
 Similarly expand the number of therapeutic agents
developed inMilestone J to 30; and the number of theseagents advanced to Phase II trials in K to more realistic
numbers (at least 12) needed to achieve Milestone L.
 In Milestone L, ensure that at least one of the agents
tested in a Phase III study is for a symptomatic
indication.
Recommended new milestones:
 Develop a uniform protocol for collecting, storing, and
providing open access to biospecimens for use in
genetics, proteomics, and other biomarker studies.
 Enlist an unbiased, independent, nonprofit entity to
conduct an annual review of clinical trial efficiencies.
 Convene a working group to consider novel trial
designs, including adaptive trials.2.1.4. Development of nonpharmacologic interventions
Milestones M through R focus on advancing research
and clinical studies, and developing best practices for the
use of nonpharmacologic interventions, both alone and in
combination with pharmacologic interventions for the pre-
vention and treatment of AD. The expert workgroup rec-
ommends revisions to the existing milestones to address
(1) the importance of treating not only cognitive and
behavioral, but also the psychological and functional
symptoms of AD; (2) the importance of developing best
practices for the use of nonpharmacologic interventions
tailored for different stages of disease, different care set-
tings (e.g., home, hospitals, assisted living, nursing
homes), and in the presence of comorbid conditions (these
best practices should include nonpharmacologic medical
approaches such as ruling out urinary tract infection); (3)
the desirability of studying biomarkers in the context of
nonpharmacologic interventions; and (4) the need to estab-
lish a theoretical rationale for using physiological out-
comes for nonpharmacologic interventions—for example,
how improvements in outcomes such as mood, sleep, or
physical function may be reflected in imaging or other
physiologic assessments.
The expert workgroup also recommends that Milestone
R, which calls for a review and assessment of technologies
used in prevention and treatment trials, lacks clarity and
needs revised wording.
Recommended modifications to existing milestones:
 Revise wording of Milestone M to include not only
cognitive and behavioral symptoms, but also func-
tional and psychological symptoms of AD; and to
develop best practices across the continuum of the dis-
ease, in different settings, and in the presence of co-
morbid conditions.
 Revise wording of Milestone N to include a range of
treatment targets (medical, psychosocial, behavioral,
environmental, and caregiver training) for the behav-
ioral, psychological, cognitive, and functional symp-
toms of AD.
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biomarker studies in the integrated interdisciplinary
research programs; and in the goals of the research,
add developing a theoretical rationale for mechanisms
by which interventions impact brain health and the
course of disease.
 Revise Milestones P and Q to include biomarker
studies in clinical trials.
 Revise Milestone R to read: Review results of past and
existing grants to develop technologies with therapeu-
tic/preventive potential (e.g., technologies used for
cognitive training, promoting or supporting physical
activity interventions, or to be used as part of a reminis-
cence, art, or music therapy program). Assess areas
where technologies have been adopted, where there
are promising results that should be followed up, and
where there are remaining needs.
Recommended new milestones:
 Initiate research programs (R01), Small Business Inno-
vative Research (SBIR), or Small Business Technology
Transfer (STTR) focused on developing and testing
new technologies or modifying and testing existing
technologies to support the development of nonphar-
macologic therapies (e.g., cognitive training, exercise
technologies).
Success Criteria: At least two new technologies are
developed, prove useful in the development of nonphar-
macologic therapies, and are widely adopted.2.2. Biomarkers of disease progression
An Alzheimer’s biomarker model of disease progression,
proposed by Jack et al. [17] and updated with new data in
2013 [18], describes the changes in Alzheimer’s biomarkers
over time, beginning decades before symptoms appear. This
model and supporting data provide not only clues about the
mechanisms underlying the disease, including amyloidosis
and neurodegeneration, but potential therapeutic targets as
well. Yet, they also point to the need for the discovery of
new biomarkers of other pathophysiologic processes
involved across the trajectory of the disease, and less intru-
sive and expensive biomarkers.
Milestones addressing these concerns focus on devel-
oping, testing, validating, and standardizing novel imaging,
cerebrospinal fluid (CSF), and blood-based biomarkers to
assess disease burden and demonstrate target engagement;
and incorporating these biomarkers into Phase II (proof of
concept) and Phase III (pivotal) drug trials for study subject
enrichment and/or proof of target engagement. The mile-
stones also call for studies linking peripheral and central bio-
markers, the development and testing of minimally invasive
biomarkers for use in clinical studies, and the development
and validation of sensitive neuropsychological assessment
measures that can track early clinical manifestations of AD.Some success has been achieved under the existing
milestones. Amyloid beta (Ab) ligands for positron emis-
sion tomography (PET) imaging are well developed—three
(florbetapir, florbetaben, and flutemetamol) have been
approved by the FDA and at least one other is in late-
stage development [19]. The approved ligands are currently
included in clinical trials, although none are yet common in
clinical use. Tau ligands are also being developed for PET
imaging [20]. Other imaging, biochemical, and genetic bio-
markers are also widely used in research and clinical
studies [21], and many novel biomarkers are in develop-
ment. Standardization has also been addressed, not only
in the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), but through the Alzheimer’s Associations’ Global
Biomarkers Standardization Consortium for Cerebrospinal
Fluid [22], the Hippocampal Harmonization Project [23],
and the Centiloid Project to standardize amyloid imaging
measures [24,25].
The expert workgroup supports the milestones that call
for development of (1) a validated tau ligand, (2) CSF bio-
markers beyond existing Ab and tau biomarkers, (3) blood-
based biomarkers directly associated with both amyloid
and tau pathology, and (4) a biomarker of synaptic dysfunc-
tion (Milestones T, U, and V). However, given that these
new biomarker milestones must be realized in parallel
with new target identification and drug development (see
section 2.1.3—Milestones I, J, K, and L), achieving these
milestones in an efficient, step-wise manner introduces
complexities related to the sharing of data, resources, and
knowledge; apportioning responsibility for funding the
various steps; and commercializing biomarker tests. For
example, once a new target is identified, preclinical studies
will be needed to establish proof of mechanism before
identification of PET tracers or other biomarkers. Subse-
quently, these biomarkers will need to be incorporated
into Phase II trials to prove mechanism and demonstrate
target engagement. The cost of development before a Phase
II study will thus require incentives for commercialization
and/or a degree of collaboration that has to this point been
difficult to bring about.
The expert workgroup endorses the milestones (Wand X)
that call for developing minimally invasive biomarkers for
detection of AD pathophysiology in community-based
studies and linking these to central imaging and CSF bio-
markers, with two modifications and one addition (see later).
With regard to developing and validating neuropsycho-
logical assessment measures for use in early Alzheimer’s
(Milestone Y), there has been substantial initial activity in
this area because theMilestones were written. The investiga-
tors from major new prospective secondary prevention trials
(DIAN, API, and A4) have come together under the Collab-
oration for Alzheimer’s Prevention (CAP) to identify com-
mon neuropsychological domains and tests to include so
that results can be shared and compared across studies.
These investigators are also working together to choose
instrumentation, on the basis of literature published over
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affected in early stages of disease. Some of these measures
are also being incorporated into other studies, including
ADNI. However, these studies are just beginning, and it is
as yet unknown whether the neuropsychological measures
chosen will prove effective. Moreover, these markers will
need to be validated both as screening/enrichment measures
and as outcome assessments to demonstrate a treatment
response.
Additional work is also needed to develop novel mea-
sures that will be sensitive and informative in presymptom-
atic Alzheimer’s. Because research suggests that subtle
cognitive changes may be detectable as changes in perfor-
mance on everyday tasks, the expert workgroup recom-
mends further studies to develop and validate measures of
cognition based on noninvasive everyday measures that
take advantage of new technologies for home monitoring,
personal monitoring via smart phones, etc.
Identification and development of novel biomarkers,
particularly for synaptic dysfunction and for minimally inva-
sive markers, is likely to require significant additional efforts
and resources in basic science and preclinical research. This
will be particularly important with regards to finding novel
biomarkers that reflect the earliest changes in the disease
process, and biomarkers that do not necessarily correlate
with existing biomarkers during disease progression and
treatment.
Recommended modifications to existing milestones:
 Revise Milestone W to reflect that the biomarkers
should not only be minimally invasive but also portable
and inexpensive (e.g., blood-based or electrophysio-
logical) to enable large studies in diverse populations.
 In Milestone X, expand the success criteria to call for
identifying at least 5 (rather than 3) peripheral blood-
based biomarkers that correlate with central (imaging
or CSF) biomarkers because 3 may be insufficient to
detect not only cerebral amyloidosis, but also neurode-
generation, inflammation, and other pathologies.
 Split or expand Milestone Y and associated success
criteria to differentiate neuropsychological assessment
measures used for trial screening/enrichment vs. those
used to assess treatment response.
Recommended new milestones:
 Validate minimally invasive biomarkers in community
studies.
 Expand existing incentives for commercialization
(e.g., expanding the funding for SBIR/STTR grants
by at least 100%), providing tax credits, and
exploring new ways to make commercial/capital in-
vestment more accessible for companies wishing to
compete in the highly regulated marketplace of med-
ical devices.
 Establish a public-private partnership to developmech-
anisms that will enable data sharing and protection orsharing of intellectual property among drug and
biomarker developers (also see section 5.3).
 Convene a conference/expo that brings together clin-
ical investigators with researchers and companies
developing technologies to capture and analyze
everyday performance measures. The goals of this
conference would be (1) to enable cross-silo discus-
sions that would promote collaborations across the
various stakeholder groups, and (2) to explore chal-
lenges that need to be addressed to make best use
of these new technologies, including privacy con-
cerns, establishing validity, and aggregating and
analyzing data.
 Establish criteria for publishing cognitive data in a way
that enables aggregation of data to facilitate compari-
son across studies.3. Infrastructure and research resources
Milestones AA through AJ are directed toward address-
ing a critical lack of sufficient research infrastructure and re-
sources to meet the research goal of the National Plan. Needs
include development and maintenance of a common AD
research ontology, expansion of epidemiological cohorts
and databases, creation of a network of translational research
centers, an NIH working group to ensure the fast-tracking of
translational research applications, the creation of a national
IRB, and the identification and implementation of standard
outcome measures.3.1. Epidemiology
Epidemiological studies have provided important infor-
mation about the natural history, incidence, prevalence,
and heterogeneity of AD, and the many possible exposures
that influence the risk of developing the disease [26]. Risk
and protective factors for dementia and Alzheimer’s identi-
fied in these studies include genetic, vascular, psychosocial,
dietary, and other lifestyle factors [27]. Thus, these studies
inform public health policies, prevention strategies, and
the design of intervention trials. The utility and importance
of epidemiologic studies have been confirmed with the
recent success reported by an early analysis of the Finnish
Geriatric Intervention Study to Prevent Cognitive Impair-
ment and Disability (FINGER) multidomain prevention trial
[28]. All the factors used as part of the intervention in this
trial—diet, physical exercise, cognitive training, social ac-
tivities, and control of vascular risk factors—were identified
through epidemiologic studies. However, more resources
must be committed to epidemiological infrastructure and
studies to fully harness the power of this methodology.
Milestones AA and AB call for convening an expert panel
to recommend best practices in the use of existing epidemi-
ology of dementia databases to individualize treatments in
Alzheimer’s clinical trials; the expansion of existing cohorts
to include subjects in mid-life; and the use of data generated
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prevention trials.
The expert workgroup called first for a reframing of these
milestones to focus more broadly on prevention of cognitive
impairment and dementia across the entire lifespan.
Although advances have been made in identifying modifi-
able risk factors that influence cognition, there remains a
need to determinewhich targets makemost sense for preven-
tion studies and the appropriate time across the life course
when prevention studies should be initiated. The workgroup
thus recommends that the work of the expert panel called for
in these milestones be expanded both in time and scope to
address these knowledge gaps and better inform future
studies. In addition the workgroup recommends building
upon existing cohort studies and/or initiating new cohort
studies with broader research goals. These studies should
be attentive to changing demographics and ethnic and racial
shifts in the population, and should have harmonized data
collection methods.
The expert workgroup further recommends the initia-
tion of a large, multidomain prevention trial focused on
modifiable risk factors in the United States to replicate
the results of the FINGER trial in a larger, more diverse
population.
Recommended modifications to existing milestones:
 In Milestone AA, extend the time frame of the expert
panel and expand the scope of the panel’s work to
include determination of best targets for prevention
and the time in the lifespan when prevention trials
make the most sense. Modify the focus more broadly
on prevention of cognitive impairment and dementia
rather than the more specific clinical trials for AD.
 Expand Milestone AB to include subjects from hetero-
geneous populations across the life course, beginning
earlier than mid-life, and expand the research on these
cohorts to include investigations of early exposures,
genetics, cumulative risk exposures, epigenetics, and
modifiable risk factors.
Recommended new milestones:
 Establish a working group to harmonize data collection
across epidemiologic studies so that data can be com-
bined and compared.
 Fund a large, multidomain prevention trial focused on
modifiable risk factors in the United States.3.2. Research ontology
Among the additional resources and infrastructure
needed to reach the goal of effectively treating and prevent-
ing Alzheimer’s by 2025, eight milestones were identified
(AC through AJ) that together will enable researchers across
multiple stakeholder groups to collaborate, share data, trans-
late discoveries into new interventions, and accelerate and
streamline clinical trials. While progress has been made inachieving some of these milestones, additional steps are
needed to accelerate progress.
Milestone AC calls for developing a common
Alzheimer’s research ontology, unified classification sys-
tem, and publicly available database of the research port-
folios of international Alzheimer’s funding agencies.
Beginning in 2010, the National Institute on Aging
(NIA) and Alzheimer’s Association began developing CA-
DRO, a Common Alzheimer’s Disease Research Ontology
[29], followed by an International Alzheimer’s Disease
Research Portfolio (IADRP) [30], which currently cap-
tures information from 15 organizations. The expert work-
group recommends two modifications to this milestone to
extend the timeline, because both CADRO and IADRP
will need continuous revisions, and to develop tools
that enable funders to track and analyze their research in-
vestments.
Recommended modifications to existing milestone:
 Extend the timeline in milestone AC, because both
CADRO and IADRP will need continuous revisions.
 Modify Milestone AC to include the development of
tools that enable funders to track and analyze their
research investments.
3.3. Partnerships
Milestones AD and AE address the need for public-private
partnerships aimed at accelerating therapy development. An
advisorymeeting was convened by the NIA in 2013 (enabling
partnerships forAlzheimer’sDiseaseDrugDevelopment), and
working groups were established to address issues that have
hindered progress in drugdevelopment, including data sharing
and analysis, translation, and intellectual property barriers.
The process led to the launching of the AD network analysis
group, which has been incorporated into the Accelerating
Medicines Partnership (AMP; see section 5.3). The expert
workgroup recommends continuing the support for this pro-
cess to promote additional dialog and effort with the goal of
developing an action plan with concrete steps.
3.4. Translational research centers
Milestones AF and AG call for creating a network of
translational research centers and expediting review of trans-
lational AD research applications. The NIH has indeed
increased its focus on translational research, establishing
the Clinical and Translational Science Awards (CTSAs) in
2006, which as of 2013 fund 62 institutions [31]; establish-
ing the NCATS in 2011, which develops collaborative pro-
jects across all sectors (industry, academia, governmental
agencies) and now oversees CTSA funding [32]; and
creating the Network for Excellence in Neuroscience Clin-
ical Trials (NeuroNext) to provide resources and infrastruc-
ture for Phase II clinical trials through public-private
partnerships [33]. However, to achieve the goal of creating
three Alzheimer’s translational centers (Milestone AF), the
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translational resources by modifying or expanding existing
Alzheimer’s Disease Centers so that they function similarly
to the National Cancer Institute’s Comprehensive Cancer
Centers, which integrate broad transdisciplinary research
programs (clinical, basic, and epidemiologic) with state-
of-the art clinical care, access to clinical trials, training of
the next generation of scientists and physicians, and public
outreach. A model for a Comprehensive ADC (CADC) at
the University of Pennsylvania was proposed in 2010 [34].
Other ADCs also have many of the components in place to
make a smooth transition to a CADC.
The expert workgroup recommends facilitating the call
for an expedited review of translational Alzheimer’s
research applications by having a nonfederal, independent
organization oversee the development and implementation
of this policy. Moreover, expedited review alone, without
available funding for projects positively reviewed, will not
achieve the goal of accelerating translational science.
Recommended modification to existing milestone:
 ForMilestone AF, the expert workgroup recommended
the following revision to the success criteria: Expan-
sion of the ADCs program with funding for three
demonstration projects to develop CADCs.
Recommended new milestones:
 Convene a workgroup to interact with the NIH to
ensure that the NIH policy on expedited review in-
cludes and achieves specific timeline targets.
 Mandate additional NIH funding to support five trans-
lational Alzheimer’s projects per year.3.5. National IRB
Milestone AH calls for creating a centralized national
IRB for neurodegenerative diseases (NIRB-ND), which
would address unnecessary inefficiencies in both time and
costs in launching multicenter studies, for which each study
site is currently required to apply individually for IRB
approval. Based on the model pioneered by the National
Cancer Institute, an NIRB-ND would provide a very high
level of expertise in neurodegenerative diseases, drawing
multidisciplinary specialist panel members from across the
United States and Canada. A small workgroup, with repre-
sentation from private foundations, academia, and the
Alzheimer’s Association, has been working on a viable
plan for the preceding two years, but thus far has received
only limited financial support commitments (from the
Alzheimer’s Association and the National Research Council
of Canada). Once established, the NIRB-ND will be finan-
cially self-sufficient. However, the effort to establish the
NIRB-ND has slowed due to lack of financial support
required from federal and industry sources needed to estab-
lish the administrative, software, computer networking,outreach and credentialing systems that will be required
for an independent, nonprofit IRB.
Recommended new milestone:
 Convene a national symposium on the centralized IRB
process, with representation from universities and
other research institutions, government, industry, and
philanthropic organizations, to 1) increase awareness
and address potential concerns of research institutions,
and 2) coordinate appropriate seed funding to launch
the national IRB.
3.6. Standardized outcome measures
Milestones AI and AJ focus on standardizing outcome
measures to be used in clinical trials, which would enable
data sharing and comparison across studies. Some progress
toward this goal has been made by CAP. However, optimal
outcome measures need to be determined for different dis-
ease stages, followed by validation and implementation.
Recommended modifications to existing milestones:
 CombineMilestones AI and AJ to achieve standardiza-
tion of clinical trial outcomemeasures to facilitate com-
parisons across trials and thereby increase the
efficiency and success of trials by (1) establishing a
forum for open sharing of data, procedures, and anal-
ysis of outcome measures; (2) initiating validation
studies across different stages of disease (preclinical,
mild cognitive impairment, dementia) that incorporate
a variety of outcomemeasures, with agreement to share
data and data analyses; and (3) developing the infra-
structure to incorporate selected outcome measures
into therapeutic trials.
3.7. Big data
Developing a comprehensive understanding of Alz-
heimer’s and related disorders, and new targets, interventions,
biomarkers, and assessment tools will require the collection,
storage, and analysis of massive amounts of diverse types of
data. The need for global “big data” solutions in Alzheimer’s
has been embraced by global organizations such as the Orga-
nisation for Economic Co-operation and Development
(OECD) [4], the G8 (now G7) Health Ministers [35], and by
national organizations in the United States, Europe, and
Japan.
The Alzheimer’s Association established the GAAIN to
bring diverse data sets together via a federated, cloud-
enabled infrastructure [15]. GAAIN enables researchers to
access data across geographical borders and also provides
computational and analytical tools. GAAIN currently con-
nects databases of the National Alzheimer’s Coordinating
Center (NACC); the National Institute on Aging Genetics
of Alzheimer’s Disease Data Storage Site, which includes
the Alzheimer’s Disease Genetics Consortium; ADNI; and
the Dominantly Inherited Alzheimer’s Network (DIAN)
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GAAIN continue to evolve, they will need to adapt to
increasingly complex and diverse types of data, including
data from multiple “omics” technologies, electronic medical
records, payer claims, biosensors, etc.; and data from an
expanded landscape of observational and clinical studies.
For example, several cohort studies have collected valuable
data on the normal and pathological process of aging; for
example, the Cardiovascular Healthy Study, the Women’s
Healthy Aging Project, the Wisconsin Registry for
Alzheimer’s Prevention, and the landmark Framingham
Heart Study [36]. Although lack of funding has curtailed
many of these projects, GAAIN will enable capture and
preservation of their data for future analysis.
The expert workgroup recommended milestones that
would strongly support national and international efforts to
build, expand, and maintain “big data” solutions, including
integrated databases such as GAAIN and other analytic plat-
forms that facilitate deep knowledge extraction of biomed-
ical research data, such as the development of in silico
modeling systems.
Recommended new milestone:
 Convene a working group that will work with global
partners to develop a strategy for sharing and harmo-
nizing data across borders.4. Study recruitment and participation
Milestones AK through AN are directed at overcoming
difficulties in clinical trial recruitment and retention. Re-
cruiting and retaining study participants in Alzheimer’s
clinical trials has proved challenging and a major hin-
drance to the successful completion of trials [37]. Many
factors contribute to sluggish recruitment, including lack
of awareness on the part of both participants [38] and pri-
mary care physicians [39], stringent inclusion and exclu-
sion criteria, and logistical issues that place unacceptable
burden on patients and caregivers. Recruitment of partici-
pants from underrepresented populations has proven
particularly difficult, despite the fact that studies report
higher Alzheimer’s risk among both African-Americans
and Hispanics [40–44]. However, African-Americans are
less likely to report cognitive and functional problems in
older family members until the impairments become
severe [41]. This highlights the need for culturally sensi-
tive educational programs that emphasize the differences
between normal and pathological cognitive aging, and
the value of research focusing on the benefits to both the
individual and the whole community now and in the future
[45,46].
Milestones addressing these concerns focus on providing
a central resource on best practices for recruitment and
retention, increasing awareness of and access to large scale
Alzheimer’s-related registries and cohorts, and increasingthe enrollment of participants from underrepresented popu-
lations in clinical trials.
Creation of a central resource for best practices in recruit-
ment and retention has been discussed by many groups
including the NIA, Alzheimer’s Association, Alzheimer’s
Disease Research Centers, the Alzheimer’s Disease Cooper-
ative Study (ADCS), and ADNI; however, there is currently
no consensus on best practices.
Recently, the US federal government has launched a
cross-agency effort to educate older adults and encourage
their participation in clinical trials. The program—named
ROAR for Recruiting Older Adults into Research—involves
the efforts of NIA, the Centers for Disease Control and Pre-
vention, and the Administration for Community Living.
After seeking input from a broad range of partners, the
ROAR group has developed educational and recruitment
materials to be used in community settings, and in conjunc-
tion with a broad range of partners, including the aging and
public health networks, and the Alzheimer’s Association.
These materials are currently being tested in several cities,
and should be expanded to include the ADCS/ADCs and in-
dustry partners.
The expert workgroup supports the idea of a central
resource for best recruitment and retention practices (such
as may be developed within the ROAR infrastructure), while
noting that consensus on best practices has not yet been
achieved and also may differ as trials move from treating
to preventing dementia. Thus, the workgroup also supports
establishing a working group of clinical trial recruitment ex-
perts to develop concrete recommendations on best recruit-
ment practices. With several large scale predementia trials
(API, DIAN, A4, TOMMORROW) already beginning to
enroll subjects, now is an ideal time to bring this working
group together to discuss the success of various recruitment
strategies (Milestones AK and AL).
With regard to increasing awareness of large-scale regis-
tries (AM and AN), tailored awareness campaigns will be
needed for different population groups concerning the pur-
pose of registries and the importance of participation. How-
ever, the expert workgroup stresses that raising awareness
alone is insufficient and must be accompanied by actually
increasing enrollment in registries, and enrollment and
retention in trials.
A national health promotion campaign to increase aware-
ness in African-American and Latino communities is
desperately needed, and regional campaigns to address the
varying needs of diverse communities. These efforts will
require both public (NIH) and private (philanthropic) funds.
The infrastructure provided by ROAR represents an opportu-
nity to build such an effort, with input from multiple stake-
holders. A task force comprising leaders in underrepresented
communities, clinical investigators, philanthropic and health
advocacy organizations, and marketing/advertising special-
ists should be convened to identify strategies for developing
these public awareness campaigns.
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 For Milestone AM, the success criteria should include
development of tailored awareness campaigns for
different populations about the purpose of registries
and the importance of participation.
 ForMilestone AN, the success criteria should include a
national health promotion campaign, and regional
campaigns to increase awareness and participation of
the African-American and Latino communities.5. Additional considerations
5.1. Novel paradigms on etiology-pathogenesis of AD
Given that current approaches to treatment have not yet
resulted in effective new therapies, strategies are needed to
re-examine existing paradigms and consider new conceptual
models of AD. The Alzheimer’s Association convened a
Research Roundtable in 2006 [47] and again in 2012 [48]
to explore mechanisms other than the dominant amyloid hy-
pothesis that may contribute to neurodegeneration in AD.
Pathways identified that may offer additional therapeutic tar-
gets include those associated with aging, such as synaptic
loss, loss of telomeres, decreased neurogenesis, autophagy,
insulin resistance, and changes in lipid metabolism; and
cell cycle events and other cellular processes such as inflam-
mation, mitochondrial dysfunction, calcium homeostasis,
and alterations in chaperone proteins.
Among the barriers to exploring these alternative hypoth-
eses has been a lack of tools, infrastructure, and resources.
Although some new tools, such as tau imaging and novel
structural and functional imaging approaches, are in devel-
opment, there remains a critical need for additional tools
including additional ligands and new technologies such as
nanoimaging. These new imaging technologies could be
especially useful in studying a cohort of individuals who
maintain cognitive function very late in life. In addition,
extensive and careful autopsy studies will continue to be
an extremely important aspect of future studies, including
proposed large, longitudinal cohort studies. However, a
rate-limiting step hindering progress in this area is the insuf-
ficient number of neuropathologists training in neurodegen-
erative disease.
In addition, substantial new efforts and resources are
needed in the area of basic science and pre-clinical research.
Clinical research depends heavily on the understanding of
basic biological and disease processes that illuminated by
basic science research. While much is known about Alz-
heimer’s disease, much remains to be discovered. Basic
research is needed to more fully understand cellular and mo-
lecular events associated with aging, and how these are tied
to the processes that give rise to Alzheimer’s disease. Areas
that are ripe for study include DNA damage, mitochondrial
function, and immunobiology. The potential for expanded
basic research to dramatically accelerate progress in transla-
tional and clinical research is enormous, and will providemuch needed illumination in areas ranging from novel ther-
apeutic strategies and targets to novel biomarkers.
Recommended new milestones:
 Establish and fund multiple training awards (e.g., K
awards), fellowships, and R01s in the neuropathology
and molecular biology of aging over the next 5 years.
 Fund a substantial research program on the basic
biology of aging, to include studies of vulnerabilities
in the aging brain, vasculature changes and endothelial
failure, neural networks, and the biological underpin-
nings of “super-aging.”
 Dramatically increase activity and resources applied to
understanding the basic cellular and molecular biology
of Alzheimer’s disease, including how these processes
interact with aging.
 Convene a working group/think tank to reexamine con-
ceptual models of disease beyond amyloid.5.2. Regulatory
The National Plan’s research goal of effectively treating
and preventing Alzheimer’s by 2025 will be achieved not
only as a result of basic and clinical research discoveries
made in academic and industry labs, but in the ability to
demonstrate through clinical trials that the treatments devel-
oped are safe and effective. The long, complicated, and
expensive process of moving a new medical entity from
the bench to the bedside has been cited as one reason for
the lack of new treatments despite rising expenditures. In
addition to novel trial designs, improvements in biomarkers
and other outcome measures, and improvements in recruit-
ment and retention of study participants, making clinical tri-
als more efficient will require greater flexibility in the
process of gaining regulatory approval for a new drug.
Regulatory agencies are key partners in this process and
have demonstrated some willingness to adapt their require-
ments to the evolving science. For example, in 2013 the
FDA published a draft guidance for developing drugs for
early stage AD [49], which suggested a willingness to
consider accelerated approval based on the demonstration
of clinical efficacy in one trial (rather than the typical
requirement of two pivotal trials) along with a biomarker
signal of target engagement. Moreover, the agency has pub-
lished guidelines for organizations to follow in seeking qual-
ification of drug development tools including biomarkers,
cognitive assessments, and modeling and simulation tools
[50]. Qualification of such tools in precompetitive space
through public-private partnerships could enable sponsors
to avoid the costly and time consuming process of validating
outcome assessments in individual trials.
Recommended new milestones:
 Define a path to validate at least one biomarker capable
of predicting clinical outcome and meet conditions for
an accelerated approval pathway by 2016; and define a
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a surrogate marker.
 Regulatory “qualification” of three or more markers of
disease progression for application to stratification of
subjects in clinical trials by 2017.
 Regulatory “white paper” or other communication,
short of guidelines, giving sense of regulators to estab-
lish appropriate principles as to degree (especially
duration and sample size) of safety data before allow-
ing years of treatment of a potentially disease prevent-
ing compound.5.3. Research financing and resource development:
Forging strategic alliances to expand the role of industry
The National Plan identifies numerous areas in which the
federal government can work collaboratively with private
research organizations, industry, and health care and
nonprofit organizations to address AD. Yet there are no mile-
stones that directly address how best to forge strategic alli-
ances with the private sector on research efforts and
expand the role of industry in this enterprise.
Most of the knowledge and expertise about drug develop-
ment and specific drugs in the pipeline reside in industry, yet
proprietary concerns make it difficult for transmission of that
knowledge to the field. There have been a few notable excep-
tions to this; for example, industry scientists from multiple
companies came together and shared data from phase I
studies of phosphodiesterase 10 (PDE10) inhibitors for
schizophrenia, increasing understanding of the disease and
helping to clarify a path forward for drug development.
Mechanisms exist within the federal government to pro-
mote collaborations with industry, such as Comparative
Research and Development Agreements. In addition, the
NIH recently established the AMP, a consortium of the
FDA, NIH, pharmaceutical companies and nonprofit
agencies, managed by the Foundation for the NIH,which
aims to jointly identify and validate disease targets for
Alzheimer’s and other diseases [51]. With $67.6 million
from the NIH and another $61.9 million from industry,
AMP is funding two 5-year Alzheimer’s projects–one
that will incorporate selected biomarkers into four
NIH-funded clinical trials and the other a network analysis
project of Alzheimer’s brain tissue samples to validate bio-
logical targets known to be involved in disease pathogen-
esis and identify new targets.
From the perspective of industry, drug development for
AD is a high-risk endeavor, exacerbated by the need for large
and lengthy clinical trials which substantially reduce the
period of marketing exclusivity. As mentioned earlier, the
FDA has addressed this to some extent by publishing a draft
guidance on developing drugs for early stage Alzheimer’s
including the use of an accelerated approval pathway
[49,52]. The accelerated approval pathway was developed
in the 1980s in response to the pressing need for drugs to
treat AIDS, and has since been used successfully foroncology drugs [53] but rarely for central nervous system
disease.
The expert workgroup recommends that more must be
done to de-risk early stage drug development and provide in-
centives to industry to devote the necessary resources to Alz-
heimer’s drug development. In industry circles, extension of
exclusivity is widely seen as the preferred solution. Another
solution that could make it economically viable for com-
panies to invest in Alzheimer’s drugs is identifying and
developing an outcome measure that provides a short-term
signal early in the drug development process.
Recommended new milestones:
 NIH/NIA/AA and other groups jointly convene a
workshop or summit to lay the groundwork for creating
a precompetitive consortium of industry partners
aimed at de-risking novel targets through the proof of
concept stage by sharing data and research tools.
 Create a consortium of industry scientists to systemat-
ically assess, stack rank, and prioritize existing targets
and conduct medicinal chemistry studies to optimize
compounds that engage these targets.
 Direct HHS to convene summit of FDA, industry law-
yers, and advocacy groups to devise incentives that
would facilitate data and resource sharing, and find so-
lutions to issues related to exclusivity.6. Summary and conclusions
Two years after the National Plan to Address Alzheimer’s
Disease was presented, the Alzheimer’s Association brought
together a multidisciplinary group of leading researchers,
clinicians, and policymakers (the expert workgroup) to eval-
uate progress in achieving the research goal of preventing
and effectively treating AD by 2025. This document de-
scribes the deliberations and recommendations of the expert
workgroup grouped into three broad areas: (1) targets, inter-
ventions, and biomarkers; (2) infrastructure and research re-
sources; and (3) study recruitment and participation. The
fourth category “additional considerations” incorporates
several areas that the expert workgroup determined were
insufficiently addressed in the existing milestones.
The expert workgroup did not specifically address the
funding needs to achieve these milestones. However, there
was broad consensus among participants in this effort that
achieving these milestones will require substantial and sus-
tained increases in support for research, combined with a
comprehensive strategy for allocating those resources
wisely.
6.1. Targets, interventions, and biomarkers (Milestones A
through Z)
These milestones address issues related to therapy devel-
opment across the entire pipeline, from discovery and valida-
tion of new therapeutic targets, the development of drugs
K.N. Fargo et al / Alzheimer’s & Dementia 10 (2014) S430–S452S450against currently known targets, the identification and testing
of existing agents in the pharmacopeia that may be repur-
posed or used in combination as treatments forAD, the devel-
opment of nonpharmacologic interventions, and the
identification of biomarkers and cognitivemarkers of disease
progression to enable efficient clinical trials of therapies.
With regard to repurposing existing drugs (Milestones A
throughD), the expert workgroup noted that despite potential
advantages arising from existing preclinical data that may be
available, there are few incentives to encourage pharmaceu-
tical companies to devote resources to repurposing efforts
when the patent life has long expired on a drug. Incentives
are also needed to encourage pharmaceutical companies to
work together toward development of combined therapies.
Cross-industry collaborations are needed, for example, to
establish a clear scientific rationale for combining therapies,
identify appropriate outcome measures, and develop innova-
tive trial designs to test drugs in combination. Given these
pressing needs, the expert workgroup recommended extend-
ing the time frame and scope, and increasing industry repre-
sentation on the repositioning and combination therapy
advisory committee established inMilestone A, and expand-
ing Milestone B to include research on the basic science un-
derlying combination therapy.
Drug development for currently known targets (Mile-
stones E and F) is well underway, yet the expert workgroup
noted that nearly all current Phase II and III trials target am-
yloid, and they called for increased efforts to develop agents
against nonamyloid targets and symptomatic therapies. Cit-
ing the high attrition rate in Phase II trials to date, they also
recommended greatly expanding the number of trials to be
initiated to achieve the success criteria indicated (three to
six successful Phase II trials and three successful Phase III
trials). They also recommended deleting the requirement
that at least two Phase II trials will be conducted in asymp-
tomatic individuals in favor of embedding proof of mecha-
nism and/or target engagement studies into Phase III trials.
The expert workgroup supportedMilestones G through L,
which focus on developing novel targets, but called for ex-
panding research efforts to go beyond the identification of
gene variants and expanding the success criteria to 12 rather
than one novel target identified. Moreover, given that only a
fraction of NMEs make it from the preclinical stage to Phase
III trials, the expert workgroup recommended greatly ex-
panding the number of NMEs identified, characterized,
and validated in Milestone I, covering six new classes of tar-
gets. Similar expansions of numbers are recommended for
drug discovery and development efforts delineated in Mile-
stones J, K, and L. In addition, they recommended that at
least one of the agents tested in a Phase III study (Milestone
L) should be for a symptomatic indication.
The expert workgroup also recommended new mile-
stones to expedite the development of novel targets,
including developing a uniform protocol for collecting, stor-
ing, and providing access to biospecimens; enlisting an un-
biased and independent entity to conduct an annual reviewof clinical trial efficiencies; and convening a working group
to consider novel trial designs such as adaptive trials.
With regard to developing nonpharmacologic interven-
tions (Milestones M through R), the expert workgroup sug-
gested revisions to the existing milestones that address
(1) the importance of treating not only cognitive and behav-
ioral, but also the psychological and functional symptoms of
Alzheimer’s; (2) the importance of developing best practices
for the use of nonpharmacologic interventions tailored for
different stages of disease, different care settings, and in
the presence of comorbid conditions; (3) the desirability of
studying biomarkers in the context of nonpharmacologic
interventions; and (4) the need to establish a theoretical
rationale for using physiological outcomes for nonpharma-
cologic interventions—for example, how improvements in
outcomes such as mood, sleep, or physical function may
be reflected in imaging or other physiologic assessments.
They also recommended an additional milestone to establish
research and business development programs focused on
developing and testing new nonpharmacologic therapies.
Citing progress that has been achieved in developing and
standardizing biomarkers, the expert workgroup endorsed
Milestones S through Z concerning the development of new
and improved biomarkers, including minimally invasive bio-
markers, and cognitive markers to assess disease progression.
However, they noted that these milestones must be realized in
parallel with new target identification and drug development,
which will require increased sharing of resources, data, and
knowledge. Thus, they recommended additional milestones
to promote collaboration and expand incentives for commer-
cialization. In addition, they suggested additional milestones
to promote the development of new functional and cognitive
measures—including noninvasive personal monitoring tech-
nologies, such as are found in cell phones—for use in
screening, enrichment, and assessing treatment response.6.2. Infrastructure and research resources (Milestones AA
through AJ)
These milestones address the critical lack of sufficient
research infrastructure and resources to meet the research
goals of the National Plan. The expert workgroup recommen-
ded expanding both the time and scope of epidemiologic
studies (Milestones AA and AB) to focus on cognitive impair-
ment across the entire lifespan and building on existing cohort
studies, or building new cohorts, to include more heteroge-
neous populations and investigate a broad range of risk factors.
The expert workgroup further recommended initiating a large,
multidomain prevention trial in the United States.
The expert workgroup recommended extending support
for resources such as the Common Alzheimer’s Disease
Research Ontology (CADRO, Milestone AC) and the Inter-
national Alzheimer’s Disease Research Portfolio (IADRP),
and public private partnerships aimed at accelerating therapy
development (Milestones AD and AE). With regard to the
creation of a network of translational research centers
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ded expanding the Alzheimer’s Disease Centers (ADCs)
program with funding for three demonstration projects to
develop Comprehensive ADCs (CADCs). The expert work-
group supported the creation of a centralized national IRB
for neurodegenerative disease (NIRB-ND, Milestone AH),
and called for a national symposium to increase awareness
and address the concerns of research institutions regarding
a national IRB. Finally, with regard to standardizing
outcome measures (Milestones AI and AJ), the expert work-
group recommended modifications to the milestones that
would facilitate comparisons across trials and increase the
efficiency and success of trials.
The expert workgroup also recommended several new
milestone to address the challenges of managing the massive
amounts of data generated across the range of Alzheimer’s-
related research studies, including developing a strategy for
sharing and harmonizing data across borders.6.3. Study recruitment and participation (milestones AK
through AN)
The expert workgroup endorsed these milestones, which
would create central resources aimed at overcoming diffi-
culties in clinical trial recruitment and retention. Recognizing
that it is especially difficult to recruit participants from under-
represented populations, they suggested revisions to the mile-
stones that would create tailored awareness campaigns for
different population groups to increase awareness and partici-
pation among theAfrican-American and Latino communities.
6.3.1. Additional considerations
The expert workgroup identified two research areas not
covered by the existing milestones, and recommended new
milestones that would address these: (1) Novel paradigms
on the etiology and pathogenesis of AD, and (2) efforts to in-
crease the efficiency of gaining regulatory approval of new
drugs. These new milestones would establish and fund
training awards, fellowships, and research programs on the
neuropathology and molecular biology of aging; and support
the regulatory qualification of several biomarkers of disease
progression.
The expert workgroup also noted the lack of milestones
that directly address how best to forge strategic alliances be-
tween the federal government and the private sector,
including expanding the role of industry in this enterprise.
Thus, they recommended efforts toward creating a precom-
petitive consortium of industry partners aimed at de-risking
early stage drug development; and a summit including a
broad range of stakeholders to address issues related to
data sharing and patent exclusivity.7. Conclusions
The expert workgroup expressed optimism that preven-
tion of AD and the development of disease modifying inter-ventions are realistic goals if all stakeholders can come
together and work in a coordinated manner toward address-
ing the scientific, financial, infrastructural, administrative,
and regulatory roadblocks that have hindered progress.
The recommendations of the expert workgroup comple-
ment parallel efforts by other global organizations such as
the OECD, World Health Organization, and the G8 Demen-
tia Summit. The Alzheimer’s Association, and the experts
who contributed to this report stand ready to work with the
HHS and the NIA to ensure that the necessary resources
and expertise are directed in the most effective manner
possible toward achieving the goal of preventing or treating
AD by 2025.References
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